Evogene Reports Q2 2026 Earnings: Improved Financials and Strategic Shift
Evogene (EVGN) reported its second-quarter earnings for 2026 with a net loss of $1.8 million, marking a significant improvement from the prior year's $4.7 million loss. The company has reduced headcount to 38 employees as part of efforts to streamline operations and focus on computational chemistry research. Evogene also expanded its virtual chemical space to 110 billion molecules through AI platform upgrades. The firm received dividends totaling over $4.25 million from Lavie Bio ($2.9 million) and Biomica ($1.35 million). Despite a decline in H1 revenue due to lower seed sales at Casterra, Evogene raised approximately $11.1 million since the beginning of 2025 through capital initiatives including an ATM program that generated $3.2 million across two quarters. Evogene's strategic shift is evident as it progresses its internal pharma pipeline and focuses on AI-driven research efficiency. The company also transitioned Casterra to focus solely on Sustainable Aviation Fuel in Brazil, while maintaining a 30% stake in Finally Foods Holding.
Tickers: $EVGN
Topics: cash flow guidance financial results headcount reduction R&D expenses